c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 128 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Bozitinib
CAS:<p>Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.</p>Formula:C20H15F3N8Purity:99.16%Color and Shape:SolidMolecular weight:424.38CSF1R-IN-2
CAS:<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>Formula:C20H20FN7O2Purity:99.29%Color and Shape:SolidMolecular weight:409.42Onartuzumab
CAS:<p>Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.</p>Purity:97.3%Color and Shape:LiquidMolecular weight:146.99 kDaPamufetinib
CAS:<p>Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.</p>Formula:C27H23FN4O4SPurity:99.39%Color and Shape:SolidMolecular weight:518.56JNJ-38877618
CAS:<p>JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).</p>Formula:C20H12F2N6Purity:98.84% - 99.74%Color and Shape:SolidMolecular weight:374.35c-Met inhibitor 1
CAS:<p>c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.</p>Formula:C17H14N8SPurity:98.77%Color and Shape:SolidMolecular weight:362.41Emibetuzumab
CAS:<p>Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.</p>Purity:SDS-PAGE:96.2%;SEC-HPLC:98.8%Color and Shape:LiquidMolecular weight:143.74 kDaRilotumumab
CAS:<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>Purity:SDS-PAGE:95% SEC-HPLC:97.51%Color and Shape:LiquidMolecular weight:145.2 kDaPF-04217903 phenolsulfonate
CAS:<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formula:C25H22N8O5SPurity:98%Color and Shape:SolidMolecular weight:546.56Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Formula:C29H49N4O10PPurity:98.01%Color and Shape:SolidMolecular weight:644.69Norleual
CAS:<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Formula:C41H58N8O7Purity:98%Color and Shape:SolidMolecular weight:774.95Antitumor agent-111
<p>Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.</p>Formula:C34H29ClF2N6O5Purity:98%Color and Shape:SolidMolecular weight:675.08c-Met-IN-18
<p>C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.</p>Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.371D228
<p>1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration of</p>Purity:98%Color and Shape:Odour SolidNarnatumab
CAS:<p>Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.</p>Purity:>95%Color and Shape:LiquidTelisotuzumab
CAS:<p>Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.</p>Purity:SDS-PAGE:96.4%;SEC-HPLC:98.5%Color and Shape:LiquidMolecular weight:145.50 kDaC-Met inhibitor D9
CAS:<p>C-Met inhibitor D9 is a c-Met kinase inhibitor.</p>Formula:C17H15N3O2Purity:97%Color and Shape:SolidMolecular weight:293.32Umikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Color and Shape:Odour LiquidPROTAC c-Met degrader-1
CAS:<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Formula:C45H41FN10O5Color and Shape:SolidMolecular weight:820.87PROTAC c-Met degrader-3
<p>PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.</p>Formula:C51H54N10O7Color and Shape:SolidMolecular weight:919.037c-Met-IN-23
<p>c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.</p>Formula:C16H13N7OMolecular weight:319.11816SU 5616
CAS:<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Formula:C13H8ClNOSPurity:98.84%Color and Shape:SoildMolecular weight:261.73BMS-777607
CAS:<p>BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.</p>Formula:C25H19ClF2N4O4Purity:98.16% - 98.56%Color and Shape:SolidMolecular weight:512.89c-Met-IN-19
<p>c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,</p>Formula:C34H37Cl2FN4O7SPurity:98%Color and Shape:SolidMolecular weight:735.65LMTK3-IN-1
CAS:<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Formula:C18H11F3N4OPurity:99.89%Color and Shape:SoildMolecular weight:356.3c-Met-IN-17
<p>c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]</p>Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37SYN1143
CAS:<p>SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.</p>Formula:C31H29FN4O5Purity:99.69%Color and Shape:SolidMolecular weight:556.58PF-04217903 methanesulfonate
CAS:<p>PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formula:C20H20N8O4SPurity:98%Color and Shape:SolidMolecular weight:468.49Merestinib dihydrochloride
CAS:<p>Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.</p>Formula:C30H24Cl2F2N6O3Color and Shape:SolidMolecular weight:625.45Afatinib Dimaleate
CAS:<p>Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.</p>Formula:C32H33ClFN5O11Purity:98.11% - 99.87%Color and Shape:SolidMolecular weight:718.08c-Kit-IN-1
CAS:<p>c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).</p>Formula:C26H21F2N5O3Purity:98.72% - 98.73%Color and Shape:SolidMolecular weight:489.47X-376
CAS:<p>X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.</p>Formula:C25H25Cl2FN6O3Purity:97.87%Color and Shape:SolidMolecular weight:547.41BMS817378
CAS:<p>BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).</p>Formula:C24H18ClF2N4O7PPurity:>99.99%Color and Shape:SolidMolecular weight:578.85Ensartinib hydrochloride
CAS:<p>Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known</p>Formula:C26H29Cl4FN6O3Purity:98.73%Color and Shape:SolidMolecular weight:634.36Glumetinib
CAS:<p>Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).</p>Formula:C21H17N9O2SPurity:99.79%Color and Shape:SolidMolecular weight:459.48Hepln-13
CAS:<p>Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.</p>Formula:C17H13BrN2Purity:97.67%Color and Shape:SolidMolecular weight:325.2Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.46NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Formula:C20H16N6Purity:97.24% - >99.99%Color and Shape:SolidMolecular weight:340.38BMS 777607
CAS:<p>BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.</p>Formula:C25H19ClF2N4O4Purity:98.30% - >99.99%Color and Shape:SolidMolecular weight:512.89MK-8033
CAS:<p>MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).</p>Formula:C25H21N5O3SPurity:97.16%Color and Shape:SolidMolecular weight:471.53Golvatinib
CAS:<p>Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor</p>Formula:C33H37F2N7O4Purity:98.24% - ≥95%Color and Shape:SolidMolecular weight:633.69AMG-337
CAS:<p>AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).</p>Formula:C23H22FN7O3Purity:99.26% - 99.9%Color and Shape:SolidMolecular weight:463.46Capmatinib 2HCl.H2O
CAS:<p>Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formula:C23H21Cl2FN6O2Purity:99.77%Color and Shape:SolidMolecular weight:503.36Foretinib
CAS:<p>Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.</p>Formula:C34H34F2N4O6Purity:98.07% - 99.68%Color and Shape:SolidMolecular weight:632.65Ningetinib
CAS:<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C31H29FN4O5Purity:99.95% - 99.98%Color and Shape:SolidMolecular weight:556.58Crizotinib hydrochloride
CAS:<p>Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)</p>Formula:C21H23Cl3FN5OPurity:98.73% - 98.87%Color and Shape:SolidMolecular weight:486.8Tivantinib
CAS:<p>Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.</p>Formula:C23H19N3O2Purity:98% - 99.41%Color and Shape:SolidMolecular weight:369.42NPS-1034
CAS:<p>NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.</p>Formula:C31H23F2N5O3Purity:98.48%Color and Shape:SolidMolecular weight:551.54CEP-40783
CAS:<p>CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).</p>Formula:C31H26F2N4O6Purity:99.76% - 99.84%Color and Shape:SolidMolecular weight:588.56Ningetinib Tosylate
CAS:<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C38H37FN4O8SPurity:99.93%Color and Shape:SolidMolecular weight:728.79Crizotinib
CAS:<p>Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.</p>Formula:C21H22Cl2FN5OPurity:99% - 99.87%Color and Shape:SolidMolecular weight:450.34AMG-208
CAS:<p>AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.</p>Formula:C22H17N5O2Purity:98.56%Color and Shape:SolidMolecular weight:383.4S49076
CAS:<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Formula:C22H22N4O4SPurity:95.35% - 97.4%Color and Shape:SolidMolecular weight:438.5DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Formula:C41H42FN5O7Purity:99.75%Color and Shape:SolidMolecular weight:735.8Capmatinib 2HCl
CAS:<p>Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.</p>Formula:C23H19Cl2FN6OPurity:98.80%Color and Shape:SolidMolecular weight:485.34SGX-523
CAS:<p>SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.</p>Formula:C18H13N7SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:359.41BMS-794833
CAS:<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Formula:C23H15ClF2N4O3Purity:98% - 99.69%Color and Shape:SolidMolecular weight:468.84XL092
CAS:<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Formula:C29H25FN4O5Purity:98.60%Color and Shape:SolidMolecular weight:528.53SCR-1481B1
CAS:<p>SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor</p>Formula:C32H40ClF2N6O13PPurity:98.07%Color and Shape:SolidMolecular weight:821.12Amuvatinib
CAS:<p>Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.</p>Formula:C23H21N5O3SPurity:99.38% - >99.99%Color and Shape:SolidMolecular weight:447.51PHA-665752
CAS:<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Formula:C32H34Cl2N4O4SPurity:97.05% - 98.82%Color and Shape:SolidMolecular weight:641.61Capmatinib
CAS:<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formula:C23H17FN6OPurity:99.24%Color and Shape:SolidMolecular weight:412.42PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Formula:C19H16N8OPurity:98.41% - 98.55%Color and Shape:SolidMolecular weight:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Formula:C25H23FN8O2S2·HClPurity:97.95%Color and Shape:SolidMolecular weight:587JNJ-38877605
CAS:<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Formula:C19H13F2N7Purity:97.04% - 98.27%Color and Shape:SolidMolecular weight:377.35Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Formula:C30H22F2N6O3Purity:95% - 99.71%Color and Shape:SolidMolecular weight:552.53MGCD-265 analog
CAS:<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Formula:C26H20FN5O2S2Purity:98.06% - 98.68%Color and Shape:SolidMolecular weight:517.6Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Formula:C17H15N9Purity:98.12%Color and Shape:SolidMolecular weight:345.36Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Formula:C23H18ClFN6OPurity:98.62% - 99.81%Color and Shape:SolidMolecular weight:448.89SRI 31215 TFA
CAS:<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Formula:C27H34F3N5O3Purity:98.25% - 99.97%Color and Shape:SolidMolecular weight:533.6Cabozantinib
CAS:<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Formula:C28H24FN3O5Purity:99.68% - 99.88%Color and Shape:SolidMolecular weight:501.51(Z)-Semaxinib
CAS:<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Formula:C15H14N2OPurity:98.82% - ≥95%Color and Shape:SolidMolecular weight:238.28Cabozantinib hydrochloride
CAS:<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Formula:C28H25ClFN3O5Purity:99.97%Color and Shape:SolidMolecular weight:537.96BAY-474
CAS:<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Formula:C17H15N5Purity:98.98%Color and Shape:SolidMolecular weight:289.33Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Formula:C24H25ClFN5O3Purity:98.56% - 99.9%Color and Shape:Off-White SolidMolecular weight:485.94Amivantamab
CAS:<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Purity:97.24% (SEC-HPLC) - 99.74%Color and Shape:LiquidMolecular weight:145.88 kDaFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Purity:95%Color and Shape:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Purity:98%Color and Shape:LiquidBafisontamab
CAS:<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Color and Shape:LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Formula:C20H11Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:380.23SU11274
CAS:<p>SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.</p>Formula:C28H30ClN5O4SPurity:98.62% - 99.53%Color and Shape:Orange PowderMolecular weight:568.09AMG-458
CAS:<p>AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.</p>Formula:C30H29N5O5Purity:99.91% - 99.98%Color and Shape:SolidMolecular weight:539.58Glesatinib
CAS:<p>Glesatinib is an orally active and potent dual inhibitor of MET/SMO.</p>Formula:C31H27F2N5O3S2Purity:98%Color and Shape:SolidMolecular weight:619.7Dalmelitinib
CAS:<p>Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.</p>Formula:C22H16FN7O2SColor and Shape:SolidMolecular weight:461.47c-Met-IN-16
CAS:<p>c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .</p>Formula:C21H17F2N9OColor and Shape:SolidMolecular weight:449.42ABN401
CAS:<p>ABN401: potent c-MET inhibitor (IC50: 10 nM), cytotoxic to MET-dependent cancers, blocks tumor c-MET phosphorylation, for cancer research.</p>Formula:C29H34N12OColor and Shape:SolidMolecular weight:566.66AC-386
CAS:<p>AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.</p>Formula:C35H34FN5O6Color and Shape:SolidMolecular weight:639.67Tyrosine kinase-IN-4
CAS:<p>Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].</p>Formula:C23H21N3O3Color and Shape:SolidMolecular weight:387.43LCRF-0004
CAS:<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Formula:C28H18F4N6O2SColor and Shape:SolidMolecular weight:578.54c-Met-IN-13
CAS:<p>c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.</p>Formula:C30H28F2N2O6Color and Shape:SolidMolecular weight:550.55SAR125844
CAS:<p>SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)</p>Formula:C25H23FN8O2S2Purity:98.73%Color and Shape:SolidMolecular weight:550.63c-Met-IN-11
CAS:<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Formula:C30H20F2N4O3Color and Shape:SolidMolecular weight:522.5Glesatinib hydrochloride
CAS:<p>Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.</p>Formula:C31H28ClF2N5O3S2Purity:98%Color and Shape:SolidMolecular weight:656.16Axl-IN-8
CAS:<p>Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).</p>Formula:C31H29FN6O3Color and Shape:SolidMolecular weight:552.6T-1840383
CAS:<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Formula:C30H25ClFN5O4Color and Shape:SolidMolecular weight:574MK-8033 hydrochloride
CAS:<p>MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.</p>Formula:C25H22ClN5O3SColor and Shape:SolidMolecular weight:507.99Mifanertinib dimaleate
CAS:<p>Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formula:C29H27ClF3N5O10Color and Shape:SolidMolecular weight:698c-Met-IN-12
CAS:<p>c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.</p>Formula:C34H29FN4O4Color and Shape:SolidMolecular weight:576.62Boditrectinib
CAS:<p>Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.</p>Formula:C23H24F2N6OColor and Shape:SolidMolecular weight:438.47Mifanertinib
CAS:<p>Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formula:C21H19ClF3N5O2Color and Shape:SolidMolecular weight:465.86
